| Drug ID: | Drug147 |
|---|
| Drug Name: | Peficitinib |
|---|
| CID: | 57928403 |
|---|
| DrugBank ID: | DB11708 |
|---|
| Modality: | Small Molecule |
|---|
| Groups: | NULL |
|---|
| US Approved: | NULL |
|---|
| Other Approved: | NULL |
|---|
| Identifier: |
NCT01959282
|
|---|
| Molecular Formula: | C18H22N4O2 |
|---|
| Molecular Weight: | 326.4 g/mol |
|---|
| Isomeric SMILES: | C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O |
|---|
| Synonyms: | Peficitinib; ASP015K; 944118-01-8; JNJ-54781532; Peficitinib [USAN:INN]; HPH1166CKX; ASP 015K; Peficitinib [USAN]; PEFICITINIB [INN]; PEFICITINIB [WHO-DD] |
|---|
| Phase 0: | 0 |
|---|
| Phase 1: | 0 |
|---|
| Phase 2: | 0 |
|---|
| Phase 3: | 0 |
|---|
| Phase 4: | 0 |
|---|
| Description: | NULL |
|---|
-
-
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
| dt1162 |
57928403 |
Peficitinib |
2185 |
PTK2B
|
Homo sapiens (human) |
|
None |
| dt1163 |
57928403 |
Peficitinib |
3718 |
JAK3
|
Homo sapiens (human) |
37713619 |
Inhibitor |
| dt1164 |
57928403 |
Peficitinib |
3716 |
JAK1
|
Homo sapiens (human) |
37713619 |
Inhibitor |
| dt1165 |
57928403 |
Peficitinib |
3718 |
JAK3
|
Homo sapiens (human) |
|
None |
| dt1166 |
57928403 |
Peficitinib |
3718 |
JAK3
|
Homo sapiens (human) |
28117214 |
Inhibition |
| dt1167 |
57928403 |
Peficitinib |
3717 |
JAK2
|
Homo sapiens (human) |
28117214 |
Inhibition |
| dt1168 |
57928403 |
Peficitinib |
3716 |
JAK1
|
Homo sapiens (human) |
28117214 |
Inhibition |
| dt1169 |
57928403 |
Peficitinib |
2047 |
EPHB1
|
Homo sapiens (human) |
|
Inhibitor |
| dt1170 |
57928403 |
Peficitinib |
3716 |
JAK1
|
Homo sapiens (human) |
|
Inhibitor |
| dt1171 |
57928403 |
Peficitinib |
2048 |
EPHB2
|
Homo sapiens (human) |
|
Inhibitor |
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
| NCT01959282 |
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… |
Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
| No data available |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
| No data available |
PMID: 29917064
Year: 2018
Relationship Type:
Treatment
Score: 7.3
BACKGROUND AND AIMS: Janus kinase [JAK] inhibitors have shown efficacy in ulcerative colitis [UC]. We studied the dose-response, efficacy, and safety…
PMID: 37572505
Year: 2023
Relationship Type:
Treatment
Score: 6.5
5-Fluorouracil (5-FU) is a conventional and effective drug for colorectal cancer patients, and it is an important part of combined chemotherapy and a…
